The World Economic Forum Recognizes Four Flagship Ventures Portfolio Companies
as Technology Pioneers for 2014
Agios Pharmaceuticals, BIND Therapeutics, Oasys Water and Selecta Biosciences
to be honored
CAMBRIDGE, Mass., Aug. 28, 2013
CAMBRIDGE, Mass., Aug. 28, 2013 /PRNewswire/ --Flagship Ventures, a leading
venture capital and venture creation firm focused on healthcare and
sustainability, today congratulates four of its portfolio companies, Agios
Pharmaceuticals, BIND Therapeutics, Oasys Water and Selecta Biosciences for
being recognized as World Economic Forum Technology Pioneers for 2014.
Agios, BIND, Oasys and Selecta are among the 36 most innovative technology
startups selected this year by the World Economic Forum for their potential to
transform the future of business and society. Flagship portfolio companies
Joule and LS9 were previously recognized as World Economic Forum Technology
Pioneers in 2012 and 2008, respectively.
"It is a great honor to see four companies, in which Flagship has been a
founding investor, simultaneously recognized for their diverse
accomplishments," said Noubar Afeyan, Managing Partner and Chief Executive
Officer of Flagship Ventures. "We are fully committed to developing and
financing startup companies based on pioneering innovations that can transform
the healthcare and sustainability industries.We congratulate Agios, BIND,
Oasys and Selecta for being recognized on this global stage and are looking
forward to their continued success."
Each year the World Economic Forum chooses a select number of Technology
Pioneers from hundreds of applicants. Candidate companies are nominated by
Members, constituents and collaborators of the World Economic Forum, and by
the public. A selection committee, comprised of top technology and innovation
experts, academics and venture capitalists, reviews all applications before
making its recommendation to the World Economic Forum.
More information about the World Economic Forum's Technology Pioneers program
can be found at http://www.weforum.org/techpioneers.
About Flagship Ventures
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The
firm operates through two synergistic units: VentureLabs™ which invents and
launches transformative companies, and Venture Capital, which finances and
develops innovative, early-stage companies. Founded in 2000, and based in
Cambridge, Massachusetts, Flagship Ventures manages over $900 million in
capital. The Flagship team is active in three principal business sectors:
therapeutics, health technologies and sustainability/clean technology. Past
successful Flagship portfolio companies include: Accuri Cytometers (acquired
by Becton, Dickinson and Company), Adnexus (acquired by Bristol-Myers Squibb),
Hypnion (acquired by Eli Lilly), Agios (NASDAQ: AGIO), AVEO (NASDAQ: AVEO), BG
Medicine (NASDAQ: BGMD), Receptos (NASDAQ: RCPT), Tetraphase (NASDAQ: TTPH),
and Morphotek (acquired by Eisai). Additional notable portfolio companies
include: Affinnova, BIND Therapeutics, Joule Unlimited, Quanterix, and Moderna
Therapeutics. For more information, please visit www.flagshipventures.com.
For Flagship Ventures: Rachel Brenner
SOURCE Flagship Ventures
Press spacebar to pause and continue. Press esc to stop.